Misplaced Pages

This is an old revision of this page, as edited by CrafterNova (talk | contribs) at 06:02, 3 October 2023 ("Na¹⁸F" is the standard scientific notation, whereas NaF¹⁸F is WP:VAGUE). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article may be too technical for most readers to understand. Please help improve it to make it understandable to non-experts, without removing the technical details. (July 2019) (Learn how and when to remove this message)

Positron emission tomography
A PET-CT scanner, with hanging pump for contrast CT
[edit on Wikidata]

Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body. For example,
F
-FDG is commonly used to detect cancer, Na
F
is widely used for detecting bone formation, and oxygen-15 is sometimes used to measure blood flow.

PET is a common imaging technique, a medical scintillography technique used in nuclear medicine. A radiopharmaceutical — a radioisotope attached to a drug — is injected into the body as a tracer. When the radiopharmaceutical undergoes beta plus decay, a positron is emitted, and when the positron interacts with an ordinary electron, the two particles annihilate and gamma rays are emitted. These gamma rays are detected by gamma cameras to form a three-dimensional image, in a similar way that an X-ray image is captured.

PET scanners can incorporate a CT scanner and are known as PET-CT scanners. PET scan images can be reconstructed using a CT scan performed using one scanner during the same session.

One of the disadvantages of a PET scanner is its high initial cost and ongoing operating costs.

Uses

PET is both a medical and research tool used in pre-clinical and clinical settings. It is used heavily in the imaging of tumors and the search for metastases within the field of clinical oncology, and for the clinical diagnosis of certain diffuse brain diseases such as those causing various types of dementias. PET is a valuable research tool to learn and enhance our knowledge of the normal human brain, heart function, and support drug development. PET is also used in pre-clinical studies using animals. It allows repeated investigations into the same subjects over time, where subjects can act as their own control and substantially reduces the numbers of animals required for a given study. This approach allows research studies to reduce the sample size needed while increasing the statistical quality of its results.

Physiological processes lead to anatomical changes in the body. Since PET is capable of detecting biochemical processes as well as expression of some proteins, PET can provide molecular-level information much before any anatomic changes are visible. PET scanning does this by using radiolabelled molecular probes that have different rates of uptake depending on the type and function of tissue involved. Regional tracer uptake in various anatomic structures can be visualized and relatively quantified in terms of injected positron emitter within a PET scan.

PET imaging is best performed using a dedicated PET scanner. It is also possible to acquire PET images using a conventional dual-head gamma camera fitted with a coincidence detector. The quality of gamma-camera PET imaging is lower, and the scans take longer to acquire. However, this method allows a low-cost on-site solution to institutions with low PET scanning demand. An alternative would be to refer these patients to another center or relying on a visit by a mobile scanner.

Alternative methods of medical imaging include single-photon emission computed tomography (SPECT), x-ray computed tomography (CT), magnetic resonance imaging (MRI) and functional magnetic resonance imaging (fMRI), and ultrasound. SPECT is an imaging technique similar to PET that uses radioligands to detect molecules in the body. SPECT is less expensive and provides inferior image quality than PET.

Oncology

PET scanning with the tracer F-FDG is widely used in clinical oncology. FDG is a glucose analog that is taken up by glucose-using cells and phosphorylated by hexokinase (whose mitochondrial form is significantly elevated in rapidly growing malignant tumors). Metabolic trapping of the radioactive glucose molecule allows the PET scan to be utilized. The concentrations of imaged FDG tracer indicate tissue metabolic activity as it corresponds to the regional glucose uptake. F-FDG is used to explore the possibility of cancer spreading to other body sites (cancer metastasis). These F-FDG PET scans for detecting cancer metastasis are the most common in standard medical care (representing 90% of current scans). The same tracer may also be used for the diagnosis of types of dementia. Less often, other radioactive tracers, usually but not always labelled with fluorine-18, are used to image the tissue concentration of different kinds of molecules of interest inside the body.

A typical dose of FDG used in an oncological scan has an effective radiation dose of 7.6 mSv. Because the hydroxy group that is replaced by fluorine-18 to generate FDG is required for the next step in glucose metabolism in all cells, no further reactions occur in FDG. Furthermore, most tissues (with the notable exception of liver and kidneys) cannot remove the phosphate added by hexokinase. This means that FDG is trapped in any cell that takes it up until it decays, since phosphorylated sugars, due to their ionic charge, cannot exit from the cell. This results in intense radiolabeling of tissues with high glucose uptake, such as the normal brain, liver, kidneys, and most cancers, which have a higher glucose uptake than most normal tissue due to the Warburg effect. As a result, FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin lymphoma, non-Hodgkin lymphoma, and lung cancer.

A 2020 review of research on the use of PET for Hodgkin lymphoma found evidence that negative findings in interim PET scans are linked to higher overall survival and progression-free survival; however, the certainty of the available evidence was moderate for survival, and very low for progression-free survival.

A few other isotopes and radiotracers are slowly being introduced into oncology for specific purposes. For example, C-labelled metomidate (11C-metomidate) has been used to detect tumors of adrenocortical origin. Also, FDOPA PET/CT (or F-18-DOPA PET/CT) has proven to be a more sensitive alternative to finding and also localizing pheochromocytoma than the MIBG scan.

Neuroimaging

Neurology

PET imaging with oxygen-15 indirectly measures blood flow to the brain. In this method, increased radioactivity signal indicates increased blood flow which is assumed to correlate with increased brain activity. Because of its 2-minute half-life, O must be piped directly from a medical cyclotron for such uses, which is difficult.

PET imaging with F-FDG takes advantage of the fact that the brain is normally a rapid user of glucose. Standard F-FDG PET of the brain measures regional glucose use and can be used in neuropathological diagnosis.

Brain pathologies such as Alzheimer's disease greatly decrease brain metabolism of both glucose and oxygen in tandem. Therefore F-FDG PET of the brain may also be used to successfully differentiate Alzheimer's disease from other dementing processes, and also to make early diagnoses of Alzheimer's disease. The advantage of F-FDG PET for these uses is its much wider availability. Some F based radioactive tracers used for Alzheimer's include florbetapir, flutemetamol, PiB and florbetaben, which are all used to detect amyloid-beta plaques (a potential biomarker for Alzheimer's) in the brain.

PET imaging with FDG can also be used for localization of seizure focus. A seizure focus will appear as hypometabolic during an interictal scan. Several radiotracers (i.e. radioligands) have been developed for PET that are ligands for specific neuroreceptor subtypes such as raclopride, fallypride and desmethoxyfallypride for dopamine D2/D3 receptors, McN 5652 and DASB for serotonin transporters, Mefway for serotonin 5HT1A receptors, Nifene for nicotinic acetylcholine receptors or enzyme substrates (e.g. 6-FDOPA for the AADC enzyme). These agents permit the visualization of neuroreceptor pools in the context of a plurality of neuropsychiatric and neurologic illnesses.

PET may also be used for the diagnosis of hippocampal sclerosis, which causes epilepsy. FDG, and the less common tracers flumazenil and MPPF have been explored for this purpose. If the sclerosis is unilateral (right hippocampus or left hippocampus), F-FDG uptake can be compared with the healthy side. Even if the diagnosis is difficult with MRI, it may be diagnosed with PET.

The development of a number of novel probes for noninvasive, in vivo PET imaging of neuroaggregate in human brain has brought amyloid imaging close to clinical use. The earliest amyloid imaging probes included 2-(1-{6-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile (FDDNP) developed at the University of California, Los Angeles and N-methyl-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (termed Pittsburgh compound B) developed at the University of Pittsburgh. These amyloid imaging probes permit the visualization of amyloid plaques in the brains of Alzheimer's patients and could assist clinicians in making a positive clinical diagnosis of AD pre-mortem and aid in the development of novel anti-amyloid therapies. PMP (N-methylpiperidin-4-yl propionate) is a novel radiopharmaceutical used in PET imaging to determine the activity of the acetylcholinergic neurotransmitter system by acting as a substrate for acetylcholinesterase. Post-mortem examination of AD patients have shown decreased levels of acetylcholinesterase. PMP is used to map the acetylcholinesterase activity in the brain, which could allow for pre-mortem diagnoses of AD and help to monitor AD treatments. Avid Radiopharmaceuticals has developed and commercialized a compound called florbetapir that uses the longer-lasting radionuclide fluorine-18 to detect amyloid plaques using PET scans.

Neuropsychology or cognitive neuroscience

To examine links between specific psychological processes or disorders and brain activity.

Psychiatry

Numerous compounds that bind selectively to neuroreceptors of interest in biological psychiatry have been radiolabeled with C-11 or F-18. Radioligands that bind to dopamine receptors (D1, D2 receptor, reuptake transporter), serotonin receptors (5HT1A, 5HT2A, reuptake transporter) opioid receptors (mu and kappa) cholinergic receptors (nicotinic and muscarinic) and other sites have been used successfully in studies with human subjects. Studies have been performed examining the state of these receptors in patients compared to healthy controls in schizophrenia, substance abuse, mood disorders and other psychiatric conditions.

Stereotactic surgery and radiosurgery

PET-image guided surgery facilitates treatment of intracranial tumors, arteriovenous malformations and other surgically treatable conditions.

Cardiology

Cardiology, atherosclerosis and vascular disease study: F-FDG PET can help in identifying hibernating myocardium. However, the cost-effectiveness of PET for this role versus SPECT is unclear. F-FDG PET imaging of atherosclerosis to detect patients at risk of stroke is also feasible. Also, it can help test the efficacy of novel anti-atherosclerosis therapies.

Infectious diseases

Imaging infections with molecular imaging technologies can improve diagnosis and treatment follow-up. Clinically, PET has been widely used to image bacterial infections using fluorodeoxyglucose (FDG) to identify the infection-associated inflammatory response. Three different PET contrast agents have been developed to image bacterial infections in vivo are maltose, maltohexaose, and 2-fluorodeoxysorbitol (FDS). FDS has the added benefit of being able to target only Enterobacteriaceae.

Bio-distribution studies

In pre-clinical trials, a new drug can be radiolabeled and injected into animals. Such scans are referred to as biodistribution studies. The information regarding drug uptake, retention and elimination over time can be obtained quickly and cost-effectively compare to the older technique of killing and dissecting the animals. Commonly, drug occupancy at a purported site of action can be inferred indirectly by competition studies between unlabeled drug and radiolabeled compounds known apriori to bind with specificity to the site. A single radioligand can be used this way to test many potential drug candidates for the same target. A related technique involves scanning with radioligands that compete with an endogenous (naturally occurring) substance at a given receptor to demonstrate that a drug causes the release of the natural substance.

Small animal imaging

A miniature animal PET has been constructed that is small enough for a fully conscious rat to be scanned. This RatCAP (Rat Conscious Animal PET) allows animals to be scanned without the confounding effects of anesthesia. PET scanners designed specifically for imaging rodents, often referred to as microPET, as well as scanners for small primates, are marketed for academic and pharmaceutical research. The scanners are based on microminiature scintillators and amplified avalanche photodiodes (APDs) through a system that uses single-chip silicon photomultipliers.

In 2018 the UC Davis School of Veterinary Medicine became the first veterinary center to employ a small clinical PET-scanner as a pet-PET scan for clinical (rather than research) animal diagnosis. Because of cost as well as the marginal utility of detecting cancer metastases in companion animals (the primary use of this modality), veterinary PET scanning is expected to be rarely available in the immediate future.

Musculo-skeletal imaging

PET imaging has been used for imaging muscles and bones. F-FDG is the most commonly used tracer for imaging muscles, and NaF-F18 is the most widely used tracer for imaging bones.

Muscles

PET is a feasible technique for studying skeletal muscles during exercises like walking. Also, PET can provide muscle activation data about deep-lying muscles (such as the vastus intermedialis and the gluteus minimus) compared to techniques like electromyography, which can be used only on superficial muscles directly under the skin. However, a disadvantage is that PET provides no timing information about muscle activation because it has to be measured after the exercise is completed. This is due to the time it takes for FDG to accumulate in the activated muscles.

Bones

Together with NaF-F18, PET for bone imaging has been in use for 60 years for measuring regional bone metabolism and blood flow using static and dynamic scans. Researchers have recently started using NaF-18 to study bone metastasis as well.

Safety

PET scanning is non-invasive, but it does involve exposure to ionizing radiation.

F-FDG, which is now the standard radiotracer used for PET neuroimaging and cancer patient management, has an effective radiation dose of 14 mSv.

The amount of radiation in F-FDG is similar to the effective dose of spending one year in the American city of Denver, Colorado (12.4 mSv/year). For comparison, radiation dosage for other medical procedures range from 0.02 mSv for a chest x-ray and 6.5–8 mSv for a CT scan of the chest. Average civil aircrews are exposed to 3 mSv/year, and the whole body occupational dose limit for nuclear energy workers in the USA is 50 mSv/year. For scale, see Orders of magnitude (radiation).

For PET-CT scanning, the radiation exposure may be substantial—around 23–26 mSv (for a 70 kg person—dose is likely to be higher for higher body weights).

Operation

Radionuclides and radiotracers

Radionuclides are incorporated either into compounds normally used by the body such as glucose (or glucose analogues), water, or ammonia, or into molecules that bind to receptors or other sites of drug action. Such labelled compounds are known as radiotracers. PET technology can be used to trace the biologic pathway of any compound in living humans (and many other species as well), provided it can be radiolabeled with a PET isotope. Thus, the specific processes that can be probed with PET are virtually limitless, and radiotracers for new target molecules and processes are continuing to be synthesized. As of this writing there are already dozens in clinical use and hundreds applied in research. In 2020 by far the most commonly used radiotracer in clinical PET scanning is the carbohydrate derivative fluorodeoxyglucose (F) (F-FDG). This radiotracer is used in essentially all scans for oncology and most scans in neurology, thus makes up the large majority of radiotracer (>95%) used in PET and PET-CT scanning.

Due to the short half-lives of most positron-emitting radioisotopes, the radiotracers have traditionally been produced using a cyclotron in close proximity to the PET imaging facility. The half-life of fluorine-18 is long enough that radiotracers labeled with fluorine-18 can be manufactured commercially at offsite locations and shipped to imaging centers. Recently rubidium-82 generators have become commercially available. These contain strontium-82, which decays by electron capture to produce positron-emitting rubidium-82.

The use of positron-emitting isotopes of metals in PET scans has been reviewed, including elements not listed above, such as lanthanides.

Immuno-PET

The isotope Zr has been applied to the tracking and quantification of molecular antibodies with positron emission tomography (PET) cameras (a method called "immuno-PET").

The biological half-life of antibodies is typically on the order of days, see daclizumab and erenumab by way of example. To visualize and quantify the distribution of such antibodies in the body, the PET isotope Zr is well suited because its physical half-life matches the typical biological half-life of antibodies, see table above.

Emission

To conduct the scan, a short-lived radioactive tracer isotope is injected into the living subject (usually into blood circulation). Each tracer atom has been chemically incorporated into a biologically active molecule. There is a waiting period while the active molecule becomes concentrated in tissues of interest. Then the subject is placed in the imaging scanner. The molecule most commonly used for this purpose is F-18 labeled fluorodeoxyglucose (FDG), a sugar, for which the waiting period is typically an hour. During the scan, a record of tissue concentration is made as the tracer decays.

As the radioisotope undergoes positron emission decay (also known as positive beta decay), it emits a positron, an antiparticle of the electron with opposite charge. The emitted positron travels in tissue for a short distance (typically less than 1 mm, but dependent on the isotope), during which time it loses kinetic energy, until it decelerates to a point where it can interact with an electron. The encounter annihilates both electron and positron, producing a pair of annihilation (gamma) photons moving in approximately opposite directions. These are detected when they reach a scintillator in the scanning device, creating a burst of light which is detected by photomultiplier tubes or silicon avalanche photodiodes (Si APD). The technique depends on simultaneous or coincident detection of the pair of photons moving in approximately opposite directions (they would be exactly opposite in their center of mass frame, but the scanner has no way to know this, and so has a built-in slight direction-error tolerance). Photons that do not arrive in temporal "pairs" (i.e. within a timing-window of a few nanoseconds) are ignored.

Localization of the positron annihilation event

The most significant fraction of electron–positron annihilations results in two 511 keV gamma photons being emitted at almost 180 degrees to each other. Hence, it is possible to localize their source along a straight line of coincidence (also called the line of response, or LOR). In practice, the LOR has a non-zero width as the emitted photons are not exactly 180 degrees apart. If the resolving time of the detectors is less than 500 picoseconds rather than about 10 nanoseconds, it is possible to localize the event to a segment of a chord, whose length is determined by the detector timing resolution. As the timing resolution improves, the signal-to-noise ratio (SNR) of the image will improve, requiring fewer events to achieve the same image quality. This technology is not yet common, but it is available on some new systems.

Image reconstruction

The raw data collected by a PET scanner are a list of 'coincidence events' representing near-simultaneous detection (typically, within a window of 6 to 12 nanoseconds of each other) of annihilation photons by a pair of detectors. Each coincidence event represents a line in space connecting the two detectors along which the positron emission occurred (i.e., the line of response (LOR)).

Analytical techniques, much like the reconstruction of computed tomography (CT) and single-photon emission computed tomography (SPECT) data, are commonly used, although the data set collected in PET is much poorer than CT, so reconstruction techniques are more difficult. Coincidence events can be grouped into projection images, called sinograms. The sinograms are sorted by the angle of each view and tilt (for 3D images). The sinogram images are analogous to the projections captured by computed tomography (CT) scanners, and can be reconstructed in a similar way. The statistics of data thereby obtained are much worse than those obtained through transmission tomography. A normal PET data set has millions of counts for the whole acquisition, while the CT can reach a few billion counts. This contributes to PET images appearing "noisier" than CT. Two major sources of noise in PET are scatter (a detected pair of photons, at least one of which was deflected from its original path by interaction with matter in the field of view, leading to the pair being assigned to an incorrect LOR) and random events (photons originating from two different annihilation events but incorrectly recorded as a coincidence pair because their arrival at their respective detectors occurred within a coincidence timing window).

In practice, considerable pre-processing of the data is required—correction for random coincidences, estimation and subtraction of scattered photons, detector dead-time correction (after the detection of a photon, the detector must "cool down" again) and detector-sensitivity correction (for both inherent detector sensitivity and changes in sensitivity due to angle of incidence).

Filtered back projection (FBP) has been frequently used to reconstruct images from the projections. This algorithm has the advantage of being simple while having a low requirement for computing resources. Disadvantages are that shot noise in the raw data is prominent in the reconstructed images, and areas of high tracer uptake tend to form streaks across the image. Also, FBP treats the data deterministically—it does not account for the inherent randomness associated with PET data, thus requiring all the pre-reconstruction corrections described above.

Statistical, likelihood-based approaches: Statistical, likelihood-based iterative expectation-maximization algorithms such as the Shepp–Vardi algorithm are now the preferred method of reconstruction. These algorithms compute an estimate of the likely distribution of annihilation events that led to the measured data, based on statistical principles. The advantage is a better noise profile and resistance to the streak artifacts common with FBP, but the disadvantage is greater computer resource requirements. A further advantage of statistical image reconstruction techniques is that the physical effects that would need to be pre-corrected for when using an analytical reconstruction algorithm, such as scattered photons, random coincidences, attenuation and detector dead-time, can be incorporated into the likelihood model being used in the reconstruction, allowing for additional noise reduction. Iterative reconstruction has also been shown to result in improvements in the resolution of the reconstructed images, since more sophisticated models of the scanner physics can be incorporated into the likelihood model than those used by analytical reconstruction methods, allowing for improved quantification of the radioactivity distribution.

Research has shown that Bayesian methods that involve a Poisson likelihood function and an appropriate prior probability (e.g., a smoothing prior leading to total variation regularization or a Laplacian distribution leading to ${\displaystyle \ell _{1}}$-based regularization in a wavelet or other domain), such as via Ulf Grenander's Sieve estimator or via Bayes penalty methods or via I.J. Good's roughness method may yield superior performance to expectation-maximization-based methods which involve a Poisson likelihood function but do not involve such a prior.

Attenuation correction: Quantitative PET Imaging requires attenuation correction. In these systems attenuation correction is based on a transmission scan using Ge rotating rod source.

Transmission scans directly measure attenuation values at 511keV. Attenuation occurs when photons emitted by the radiotracer inside the body are absorbed by intervening tissue between the detector and the emission of the photon. As different LORs must traverse different thicknesses of tissue, the photons are attenuated differentially. The result is that structures deep in the body are reconstructed as having falsely low tracer uptake. Contemporary scanners can estimate attenuation using integrated x-ray CT equipment, in place of earlier equipment that offered a crude form of CT using a gamma ray (positron emitting) source and the PET detectors.

While attenuation-corrected images are generally more faithful representations, the correction process is itself susceptible to significant artifacts. As a result, both corrected and uncorrected images are always reconstructed and read together.

2D/3D reconstruction: Early PET scanners had only a single ring of detectors, hence the acquisition of data and subsequent reconstruction was restricted to a single transverse plane. More modern scanners now include multiple rings, essentially forming a cylinder of detectors.

There are two approaches to reconstructing data from such a scanner: \ 1) treat each ring as a separate entity, so that only coincidences within a ring are detected, the image from each ring can then be reconstructed individually (2D reconstruction), or 2) allow coincidences to be detected between rings as well as within rings, then reconstruct the entire volume together (3D).

3D techniques have better sensitivity (because more coincidences are detected and used) hence less noise, but are more sensitive to the effects of scatter and random coincidences, as well as requiring greater computer resources. The advent of sub-nanosecond timing resolution detectors affords better random coincidence rejection, thus favoring 3D image reconstruction.

Time-of-flight (TOF) PET: For modern systems with a higher time resolution (roughly 3 nanoseconds) a technique called "time-of-flight" is used to improve the overall performance. Time-of-flight PET makes use of very fast gamma-ray detectors and data processing system which can more precisely decide the difference in time between the detection of the two photons. It is impossible to localize the point of origin of the annihilation event exactly (currently within 10 cm). Therefore, image reconstruction is still needed. TOF technique gives a remarkable improvement in image quality, especially signal-to-noise ratio.

Combination of PET with CT or MRI

PET scans are increasingly read alongside CT or magnetic resonance imaging (MRI) scans, with the combination (called "co-registration") giving both anatomic and metabolic information (i.e., what the structure is, and what it is doing biochemically). Because PET imaging is most useful in combination with anatomical imaging, such as CT, modern PET scanners are now available with integrated high-end multi-detector-row CT scanners (so-called "PET-CT"). Because the two scans can be performed in immediate sequence during the same session, with the patient not changing position between the two types of scans, the two sets of images are more precisely registered, so that areas of abnormality on the PET imaging can be more perfectly correlated with anatomy on the CT images. This is very useful in showing detailed views of moving organs or structures with higher anatomical variation, which is more common outside the brain.

At the Jülich Institute of Neurosciences and Biophysics, the world's largest PET-MRI device began operation in April 2009. A 9.4-tesla magnetic resonance tomograph (MRT) combined with a positron emission tomograph (PET). Presently, only the head and brain can be imaged at these high magnetic field strengths.

For brain imaging, registration of CT, MRI and PET scans may be accomplished without the need for an integrated PET-CT or PET-MRI scanner by using a device known as the N-localizer.

Limitations

The minimization of radiation dose to the subject is an attractive feature of the use of short-lived radionuclides. Besides its established role as a diagnostic technique, PET has an expanding role as a method to assess the response to therapy, in particular, cancer therapy, where the risk to the patient from lack of knowledge about disease progress is much greater than the risk from the test radiation. Since the tracers are radioactive, the elderly and pregnant are unable to use it due to risks posed by radiation.

Limitations to the widespread use of PET arise from the high costs of cyclotrons needed to produce the short-lived radionuclides for PET scanning and the need for specially adapted on-site chemical synthesis apparatus to produce the radiopharmaceuticals after radioisotope preparation. Organic radiotracer molecules that will contain a positron-emitting radioisotope cannot be synthesized first and then the radioisotope prepared within them, because bombardment with a cyclotron to prepare the radioisotope destroys any organic carrier for it. Instead, the isotope must be prepared first, then the chemistry to prepare any organic radiotracer (such as FDG) accomplished very quickly, in the short time before the isotope decays. Few hospitals and universities are capable of maintaining such systems, and most clinical PET is supported by third-party suppliers of radiotracers that can supply many sites simultaneously. This limitation restricts clinical PET primarily to the use of tracers labelled with fluorine-18, which has a half-life of 110 minutes and can be transported a reasonable distance before use, or to rubidium-82 (used as rubidium-82 chloride) with a half-life of 1.27 minutes, which is created in a portable generator and is used for myocardial perfusion studies. In recent years a few on-site cyclotrons with integrated shielding and "hot labs" (automated chemistry labs that are able to work with radioisotopes) have begun to accompany PET units to remote hospitals. The presence of the small on-site cyclotron promises to expand in the future as the cyclotrons shrink in response to the high cost of isotope transportation to remote PET machines. In recent years the shortage of PET scans has been alleviated in the US, as rollout of radiopharmacies to supply radioisotopes has grown 30%/year.

Because the half-life of fluorine-18 is about two hours, the prepared dose of a radiopharmaceutical bearing this radionuclide will undergo multiple half-lives of decay during the working day. This necessitates frequent recalibration of the remaining dose (determination of activity per unit volume) and careful planning with respect to patient scheduling.

History

The concept of emission and transmission tomography was introduced by David E. Kuhl, Luke Chapman and Roy Edwards in the late 1950s. Their work later led to the design and construction of several tomographic instruments at the University of Pennsylvania. In 1975 tomographic imaging techniques were further developed by Michel Ter-Pogossian, Michael E. Phelps, Edward J. Hoffman and others at Washington University School of Medicine.

Work by Gordon Brownell, Charles Burnham and their associates at the Massachusetts General Hospital beginning in the 1950s contributed significantly to the development of PET technology and included the first demonstration of annihilation radiation for medical imaging. Their innovations, including the use of light pipes and volumetric analysis, have been important in the deployment of PET imaging. In 1961, James Robertson and his associates at Brookhaven National Laboratory built the first single-plane PET scan, nicknamed the "head-shrinker."

One of the factors most responsible for the acceptance of positron imaging was the development of radiopharmaceuticals. In particular, the development of labeled 2-fluorodeoxy-D-glucose (2FDG) by the Brookhaven group under the direction of Al Wolf and Joanna Fowler was a major factor in expanding the scope of PET imaging. The compound was first administered to two normal human volunteers by Abass Alavi in August 1976 at the University of Pennsylvania. Brain images obtained with an ordinary (non-PET) nuclear scanner demonstrated the concentration of FDG in that organ. Later, the substance was used in dedicated positron tomographic scanners, to yield the modern procedure.

The logical extension of positron instrumentation was a design using two 2-dimensional arrays. PC-I was the first instrument using this concept and was designed in 1968, completed in 1969 and reported in 1972. The first applications of PC-I in tomographic mode as distinguished from the computed tomographic mode were reported in 1970. It soon became clear to many of those involved in PET development that a circular or cylindrical array of detectors was the logical next step in PET instrumentation. Although many investigators took this approach, James Robertson and Zang-Hee Cho were the first to propose a ring system that has become the prototype of the current shape of PET. Hi The PET-CT scanner, attributed to David Townsend and Ronald Nutt, was named by Time as the medical invention of the year in 2000.

Cost

This section needs to be updated. Please help update this article to reflect recent events or newly available information. (February 2018)

As of August 2008, Cancer Care Ontario reports that the current average incremental cost to perform a PET scan in the province is Can$1,000–1,200 per scan. This includes the cost of the radiopharmaceutical and a stipend for the physician reading the scan.

In the United States, a PET scan is estimated to be ~$5,000, and most insurance companies don't pay for routine PET scans after cancer treatment due to the fact that these scans are often unnecessary and present potentially more risks than benefits.

In England, the National Health Service reference cost (2015–2016) for an adult outpatient PET scan is £798.

In Australia, as of July 2018, the Medicare Benefits Schedule Fee for whole body FDG PET ranges from A$953 to A$999, depending on the indication for the scan.

Quality control

The overall performance of PET systems can be evaluated by quality control tools such as the Jaszczak phantom.

See also

• Diffuse optical imaging
• Hot cell (equipment used to produce the radiopharmaceuticals used in PET)
• Molecular imaging

References

1. ^ Bailey DL, Townsend DW, Valk PE, Maisy MN (2005). Positron Emission Tomography: Basic Sciences. Secaucus, NJ: Springer-Verlag. ISBN 978-1-85233-798-8.
2. "Nuclear Medicine". hyperphysics.phy-astr.gsu.edu. Retrieved 11 December 2022.
3. ^ Carlson N (22 January 2012). Physiology of Behavior. Methods and Strategies of Research. Vol. 11th edition. Pearson. p. 151. ISBN 978-0205239399.
4. ^ ARSAC - Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and use of Sealed Sources (March 2018 p.35)
5. Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A (July 2019). "The role of PET/CT in the modern treatment of Hodgkin lymphoma". Cancer Treatment Reviews. 77: 44–56. doi:10.1016/j.ctrv.2019.06.002. PMID 31260900. S2CID 195772317.
6. McCarten KM, Nadel HR, Shulkin BL, Cho SY (October 2019). "Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma". Pediatric Radiology. 49 (11): 1545–1564. doi:10.1007/s00247-019-04529-8. PMID 31620854. S2CID 204707264.
7. Pauls S, Buck AK, Hohl K, Halter G, Hetzel M, Blumstein NM, et al. (2007). "Improved non-invasive T-Staging in non-small cell lung cancer by integrated18F-FDG PET/CT". Nuklearmedizin. 46 (1): 09–14. doi:10.1055/s-0037-1616618. ISSN 0029-5566. S2CID 21791308.
8. Steinert HC (2011). "PET and PET-CT of lung cancer". Positron Emission Tomography. Methods in Molecular Biology. Vol. 727. Humana Press. pp. 33–51. doi:10.1007/978-1-61779-062-1_3. ISBN 978-1-61779-061-4. PMID 21331927.
9. Chao F, Zhang H (2012). "PET/CT in the staging of the non-small-cell lung cancer". Journal of Biomedicine & Biotechnology. 2012: 783739. doi:10.1155/2012/783739. PMC 3346692. PMID 22577296.
10. Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. (Cochrane Haematology Group) (January 2020). "Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies". The Cochrane Database of Systematic Reviews. 1 (1): CD012643. doi:10.1002/14651858.CD012643.pub3. PMC 6984446. PMID 31930780.
11. Khan TS, Sundin A, Juhlin C, Långström B, Bergström M, Eriksson B (March 2003). "11C-metomidate PET imaging of adrenocortical cancer". European Journal of Nuclear Medicine and Molecular Imaging. 30 (3): 403–10. doi:10.1007/s00259-002-1025-9. PMID 12634969. S2CID 23744095.
12. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Långsjö J, et al. (June 2004). "Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG". Journal of Nuclear Medicine. 45 (6): 972–9. PMID 15181132.
13. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS (July 2001). "6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma". Hypertension. 38 (1): 6–8. doi:10.1161/01.HYP.38.1.6. PMID 11463751.
14. "Pheochromocytoma Imaging: Overview, Radiography, Computed Tomography". 10 August 2017 – via eMedicine. {{cite journal}}: Cite journal requires |journal= (help)
15. Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. (March 2010). "Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma". European Journal of Nuclear Medicine and Molecular Imaging. 37 (3): 484–93. doi:10.1007/s00259-009-1294-7. PMID 19862519. S2CID 10147392.
16. Cherry, Simon R. (2012). Physics in Nuclear Medicine (4th ed.). Philadelphia: Saunders. p. 60. ISBN 9781416051985.
17. Anand, Keshav; Sabbagh, Marwan (January 2017). "Amyloid Imaging: Poised for Integration into Medical Practice". Neurotherapeutics. 14 (1): 54–61. doi:10.1007/s13311-016-0474-y. PMC 5233621. PMID 27571940.
18. Stanescu, Luana; Ishak, Gisele E.; Khanna, Paritosh C.; Biyyam, Deepa R.; Shaw, Dennis W.; Parisi, Marguerite T. (September 2013). "FDG PET of the Brain in Pediatric Patients: Imaging Spectrum with MR Imaging Correlation". RadioGraphics. 33 (5): 1279–1303. doi:10.1148/rg.335125152. PMID 24025925.
19. la Fougère, C.; Rominger, A.; Förster, S.; Geisler, J.; Bartenstein, P. (May 2009). "PET and SPECT in epilepsy: A critical review". Epilepsy & Behavior. 15 (1): 50–55. doi:10.1016/j.yebeh.2009.02.025. PMID 19236949.
20. Hodolic, Marina; Topakian, Raffi; Pichler, Robert (1 September 2016). "18 F-fluorodeoxyglucose and 18 F-flumazenil positron emission tomography in patients with refractory epilepsy". Radiology and Oncology. 50 (3): 247–253. doi:10.1515/raon-2016-0032. PMC 5024661. PMID 27679539.
21. Malmgren, K; Thom, M (September 2012). "Hippocampal sclerosis--origins and imaging". Epilepsia. 53 (Suppl 4): 19–33. doi:10.1111/j.1528-1167.2012.03610.x. PMID 22946718.
22. Cendes, Fernando (June 2013). "Neuroimaging in Investigation of Patients With Epilepsy". Continuum. 19 (3 Epilepsy): 623–642. doi:10.1212/01.CON.0000431379.29065.d3. PMID 23739101. S2CID 19026991.
23. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. (December 2001). "Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease". The Journal of Neuroscience. 21 (24): RC189. doi:10.1523/JNEUROSCI.21-24-j0004.2001. PMC 6763047. PMID 11734604.
24. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. (February 2002). "A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain". Bioorganic & Medicinal Chemistry Letters. 12 (3): 295–8. doi:10.1016/S0960-894X(01)00734-X. PMID 11814781.
25. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, et al. (March 1999). "In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease". Neurology. 52 (4): 691–9. doi:10.1212/wnl.52.4.691. PMID 10078712. S2CID 11057426.
26. Kolata, Gina. "Promise Seen for Detection of Alzheimer's", The New York Times, June 23, 2010. Accessed June 23, 2010.
27. Catafau AM, Searle GE, Bullich S, Gunn RN, Rabiner EA, Herance R, et al. (May 2010). "Imaging cortical dopamine D1 receptors using [11C]NNC112 and ketanserin blockade of the 5-HT 2A receptors". Journal of Cerebral Blood Flow and Metabolism. 30 (5): 985–93. doi:10.1038/jcbfm.2009.269. PMC 2949183. PMID 20029452.
28. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J (December 2002). "Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors". Synapse. 46 (3): 170–88. doi:10.1002/syn.10128. PMID 12325044. S2CID 24852944.
29. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, et al. (July 2006). "D2/D3 dopamine receptor binding with fallypride in thalamus and cortex of patients with schizophrenia". Schizophrenia Research. 85 (1–3): 232–44. doi:10.1016/j.schres.2006.03.042. PMID 16713185. S2CID 45446283.
30. ^ Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. (July 2004). "Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification". Journal of Nuclear Medicine. 45 (7): 1146–54. PMID 15235060.
31. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. (June 2002). "Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography". Circulation. 105 (23): 2708–11. doi:10.1161/01.CIR.0000020548.60110.76. PMID 12057982.
32. Gowrishankar G, Namavari M, Jouannot EB, Hoehne A, Reeves R, Hardy J, Gambhir SS (2014). "Investigation of 6-[F]-fluoromaltose as a novel PET tracer for imaging bacterial infection". PLOS ONE. 9 (9): e107951. Bibcode:2014PLoSO...9j7951G. doi:10.1371/journal.pone.0107951. PMC 4171493. PMID 25243851.
33. Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, et al. (October 2014). "Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography". Science Translational Medicine. 6 (259): 259ra146. doi:10.1126/scitranslmed.3009815. PMC 4327834. PMID 25338757.
34. Laruelle M (March 2000). "Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review". Journal of Cerebral Blood Flow and Metabolism. 20 (3): 423–51. doi:10.1097/00004647-200003000-00001. PMID 10724107.
35. "Rat Conscious Animal PET". Archived from the original on 5 March 2012.
36. Oi N, Iwaya T, Itoh M, Yamaguchi K, Tobimatsu Y, Fujimoto T (2003). "FDG-PET imaging of lower extremity muscular activity during level walking". Journal of Orthopaedic Science. 8 (1): 55–61. doi:10.1007/s007760300009. PMID 12560887. S2CID 23698288.
37. Azad GK, Siddique M, Taylor B, Green A, O'Doherty J, Gariani J, et al. (March 2019). "18F-Fluoride PET/CT SUV?". Journal of Nuclear Medicine. 60 (3): 322–327. doi:10.2967/jnumed.118.208710. PMC 6424232. PMID 30042160.
38. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. (April 2005). "Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development". Clinical Cancer Research. 11 (8): 2785–808. doi:10.1158/1078-0432.CCR-04-2626. PMID 15837727.
39. "Institute for Science and International Security". isis-online.org.
40. Managing Patient Does, ICRP, 30 October 2009.
41. de Jong PA, Tiddens HA, Lequin MH, Robinson TE, Brody AS (May 2008). "Estimation of the radiation dose from CT in cystic fibrosis". Chest. 133 (5): 1289–91, author reply 1290–1. doi:10.1378/chest.07-2840. PMID 18460535.
42. "Chapter 9 Occupational Exposure to Radiation" (PDF). Radiation, People and the Environment. IAEA. pp. 39–42. Archived from the original (PDF) on 5 July 2008.
43. "NRC: Information for Radiation Workers". www.nrc.gov. Retrieved 21 June 2020.
44. Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T (April 2005). "Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations". Journal of Nuclear Medicine. 46 (4): 608–13. PMID 15809483.
45. Wootton R, Doré C (November 1986). "The single-passage extraction of 18F in rabbit bone". Clinical Physics and Physiological Measurement. 7 (4): 333–43. Bibcode:1986CPPM....7..333W. doi:10.1088/0143-0815/7/4/003. PMID 3791879.
46. Dilworth JR, Pascu SI (April 2018). "The chemistry of PET imaging with zirconium-89". Chemical Society Reviews. 47 (8): 2554–2571. doi:10.1039/C7CS00014F. PMID 29557435.
47. Bracco Diagnostics, CardioGen-82 Archived 6 September 2011 at the Wayback Machine, 2000
48. Ahn, Shin Hye; Cosby, Alexia G.; Koller, Angus J.; Martin, Kirsten E.; Pandey, Apurva; Vaughn, Brett A.; Boros, Eszter (2021). "Chapter 6. Radiometals for Positron Emission Tomography (PET) Imaging". Metal Ions in Bio-Imaging Techniques. Springer. pp. 157–194. doi:10.1515/9783110685701-012. S2CID 233679785.
49. Heuveling, Derek A.; Visser, Gerard W. M.; Baclayon, Marian; Roos, Wouter H.; Wuite, Gijs J. L.; Hoekstra, Otto S.; Leemans, C. René; de Bree, Remco; van Dongen, Guus A. M. S. (2011). "Zr-Nanocolloidal Albumin–Based PET/CT Lymphoscintigraphy for Sentinel Node Detection in Head and Neck Cancer: Preclinical Results" (PDF). The Journal of Nuclear Medicine. 52 (10): 1580–1584. doi:10.2967/jnumed.111.089557. PMID 21890880. S2CID 21902223.
50. van Rij, Catharina M.; Sharkey, Robert M.; Goldenberg, David M.; Frielink, Cathelijne; Molkenboer, Janneke D. M.; Franssen, Gerben M.; van Weerden, Wietske M.; Oyen, Wim J. G.; Boerman, Otto C. (2011). "Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody". The Journal of Nuclear Medicine. 52 (10): 1601–1607. doi:10.2967/jnumed.110.086520. PMID 21865288.
51. Ruggiero, A.; Holland, J. P.; Hudolin, T.; Shenker, L.; Koulova, A.; Bander, N. H.; Lewis, J. S.; Grimm, J. (2011). "Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET". The Journal of Nuclear Medicine. 52 (10): 1608–15. doi:10.2967/jnumed.111.092098. PMC 3537833. PMID 21908391.
52. Phelps ME (2006). PET: physics, instrumentation, and scanners. Springer. pp. 8–10. ISBN 978-0-387-34946-6.
53. "PET Imaging". GE Healthcare. Archived from the original on 4 May 2012.
54. "Invitation to Cover: Advancements in "Time-of-Flight" Technology Make New PET/CT Scanner at Penn a First in the World". University of Pennsylvania. 15 June 2006. Archived from the original on 28 June 2006. Retrieved 22 February 2010.
55. Lange K, Carson R (April 1984). "EM reconstruction algorithms for emission and transmission tomography". Journal of Computer Assisted Tomography. 8 (2): 306–16. PMID 6608535.
56. Vardi Y, Shepp LA, Kaufman L (1985). "A statistical model for positron emission tomography". Journal of the American Statistical Association. 80 (389): 8–37. doi:10.1080/01621459.1985.10477119. S2CID 17836207.
57. Shepp LA, Vardi Y (1982). "Maximum likelihood reconstruction for emission tomography". IEEE Transactions on Medical Imaging. 1 (2): 113–22. doi:10.1109/TMI.1982.4307558. PMID 18238264.
58. Qi J, Leahy RM (August 2006). "Iterative reconstruction techniques in emission computed tomography". Physics in Medicine and Biology. 51 (15): R541-78. Bibcode:2006PMB....51R.541Q. doi:10.1088/0031-9155/51/15/R01. PMID 16861768. S2CID 40488776.
59. Snyder DL, Miller M (1985). "On the Use of the Method of Sieves for Positron Emission Tomography". IEEE Transactions on Medical Imaging. NS-32(5) (5): 3864–3872. Bibcode:1985ITNS...32.3864S. doi:10.1109/TNS.1985.4334521. S2CID 2112617.
60. Geman S, McClure DE (1985). "Bayesian image analysis: An application to single photon emission tomography" (PDF). Proceedings Amererican Statistical Computing: 12–18.
61. Snyder DL, Miller MI, Thomas LJ, Politte DG (1987). "Noise and edge artifacts in maximum-likelihood reconstructions for emission tomography". IEEE Transactions on Medical Imaging. 6 (3): 228–38. doi:10.1109/tmi.1987.4307831. PMID 18244025. S2CID 30033603.
62. Green PJ (1990). "Bayesian reconstructions from emission tomography data using a modified EM algorithm" (PDF). IEEE Transactions on Medical Imaging. 9 (1): 84–93. CiteSeerX 10.1.1.144.8671. doi:10.1109/42.52985. PMID 18222753.
63. Miller MI, Snyder DL (1987). "The role of likelihood and entropy in incomplete data problems: Applications to estimating point-process intensites and toeplitz constrained covariance estimates". Proceedings of the IEEE. 5 (7): 892–907. doi:10.1109/PROC.1987.13825. S2CID 23733140.
64. Miller MI, Roysam B (April 1991). "Bayesian image reconstruction for emission tomography incorporating Good's roughness prior on massively parallel processors". Proceedings of the National Academy of Sciences of the United States of America. 88 (8): 3223–7. Bibcode:1991PNAS...88.3223M. doi:10.1073/pnas.88.8.3223. PMC 51418. PMID 2014243.
65. Willett R, Harmany Z, Marcia R (2010). "Poisson image reconstruction with total variation regularization". 17th IEEE International Conference on Image Processing. pp. 4177–4180. CiteSeerX 10.1.1.175.3149. doi:10.1109/ICIP.2010.5649600. ISBN 978-1-4244-7992-4. S2CID 246589.
66. Harmany Z, Marcia R, Willett R (2010). "Sparsity-regularized Photon-limited Imaging". International Symposium on Biomedical Imaging (ISBI).
67. Willett R, Harmany Z, Marcia R (2010). Bouman CA, Pollak I, Wolfe PJ (eds.). "SPIRAL out of Convexity: Sparsity-regularized Algorithms for Photon-limited Imaging". SPIE Electronic Imaging. Computational Imaging VIII. 7533: 75330R. Bibcode:2010SPIE.7533E..0RH. CiteSeerX 10.1.1.175.3054. doi:10.1117/12.850771. S2CID 7172003.
68. Huang SC, Hoffman EJ, Phelps ME, Kuhl DE (December 1979). "Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction". Journal of Computer Assisted Tomography. 3 (6): 804–14. doi:10.1097/00004728-197903060-00018. PMID 315970.
69. Navalpakkam BK, Braun H, Kuwert T, Quick HH (May 2013). "Magnetic resonance-based attenuation correction for PET/MR hybrid imaging using continuous valued attenuation maps". Investigative Radiology. 48 (5): 323–32. doi:10.1097/rli.0b013e318283292f. PMID 23442772. S2CID 21553206.
70. Wagenknecht G, Kaiser HJ, Mottaghy FM, Herzog H (February 2013). "MRI for attenuation correction in PET: methods and challenges". Magma. 26 (1): 99–113. doi:10.1007/s10334-012-0353-4. PMC 3572388. PMID 23179594.
71. "A Close Look Into the Brain". Jülich Research Centre. 7 March 2014. Retrieved 14 April 2015.
72. Tse VC, Kalani MY, Adler JR (2015). "Techniques of Stereotactic Localization". In Chin LS, Regine WF (eds.). Principles and Practice of Stereotactic Radiosurgery. New York: Springer. p. 28.
73. Saleh H, Kassas B (2015). "Developing Stereotactic Frames for Cranial Treatment". In Benedict SH, Schlesinger DJ, Goetsch SJ, Kavanagh BD (eds.). Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Boca Raton: CRC Press. pp. 156–159.
74. Khan FR, Henderson JM (2013). "Deep Brain Stimulation Surgical Techniques". In Lozano AM, Hallet M (eds.). Brain Stimulation: Handbook of Clinical Neurology. Handbook of Clinical Neurology. Vol. 116. Amsterdam: Elsevier. pp. 28–30. doi:10.1016/B978-0-444-53497-2.00003-6. ISBN 9780444534972. PMID 24112882.
75. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. (December 1999). "Measurement of clinical and subclinical tumor response using -fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group". European Journal of Cancer. 35 (13): 1773–82. doi:10.1016/S0959-8049(99)00229-4. PMID 10673991.
76. Fratt L (July 2003). "Technology". Medical Imaging. Archived from the original on 20 November 2008.
77. Phelps M (16 January 2013). "PET History and Overview" (PDF). Crump Institute for Molecular Imaging. Archived from the original (PDF) on 18 May 2015.
78. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA (January 1975). "A positron-emission transaxial tomograph for nuclear imaging (PETT)". Radiology. 114 (1): 89–98. doi:10.1148/114.1.89. OSTI 4251398. PMID 1208874.
79. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (March 1975). "Application of annihilation coincidence detection to transaxial reconstruction tomography". Journal of Nuclear Medicine. 16 (3): 210–24. PMID 1113170.
80. Sweet WH, Brownell GL (1953). "Localization of brain tumors with positron emitters". Nucleonics. 11: 40–45.
81. A Vital Legacy: Biological and Environmental Research in the Atomic Age (Report). U.S. Department of Energy, The Office of Biological and Environmental Research. September 2010. pp. 25–26.
82. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE (1978). "Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose". Journal of Labelled Compounds and Radiopharmaceuticals. 14 (2): 175–183. doi:10.1002/jlcr.2580140204.
83. Brownell GL, Burnham CA, Hoop Jr B, Bohning DE (August 1945). Quantitative dynamic studies using short-lived radioisotopes and positron detection. Symposium on Dynamic Studies with Radioisotopes in Medicine. Rotterdam: IAEA Vienna. pp. 161–172.
84. Robertson JS, Marr RB, Rosenblum M, Radeka V, Yamamoto YL (1983). "32-Crystal positron transverse section detector". In Freedman GS (ed.). Tomographic Imaging in Nuclear Medicine. New York: The Society of Nuclear Medicine. pp. 142–153.
85. Cho ZH, Eriksson L, Chan JK (1975). "A circular ring transverse axial positron camera". In Ter-Pogossian MM (ed.). Reconstruction Tomography in Diagnostic Radiology and Nuclear Medicine. Baltimore: University Park Press.
86. "PET Scan: PET/CT History". Petscaninfo.com. Archived from the original on 14 April 2012. Retrieved 13 August 2012.
87. Ontario PET Steering Committee (31 August 2008), PET SCAN PRIMER, A Guide to the Implementation of Positron Emission Tomography Imaging in Ontario, Executive Summary, pp. iii
88. "PET Scans After Cancer Treatment | Choosing Wisely". www.choosingwisely.org. June 2014. Retrieved 1 April 2019.
89. "NHS reference costs 2015 to 2016". Department of Health. 15 December 2016. Retrieved 22 December 2016.
90. "MBS online". Australian Government Department of Health. Retrieved 16 October 2018.
91. Prekeges, Jennifer (2012). Nuclear Medicine Instrumentation. Jones & Bartlett Publishers. ISBN 1449645372. p. 189.

External links

• Resources in your library

• Hofman MS, Hicks RJ (October 2016). "How We Read Oncologic FDG PET/CT". Cancer Imaging. 16 (1): 35. doi:10.1186/s40644-016-0091-3. PMC 5067887. PMID 27756360.
• PET-CT atlas Harvard Medical School Archived 11 May 2019 at the Wayback Machine
• National Isotope Development Center—U.S. government source of radionuclides including those for PET—production, research, development, distribution, and information

• Positron emission tomography
• 3D nuclear medical imaging
• American inventions
• Medical physics
• Neuroimaging
• Radiation therapy
• Medicinal radiochemistry
• Armenian inventions
• Positron